Crystal methamphetamine smoking among regular ecstasy users in Australia: Increases in use and associations with harm

Drug and Alcohol Review

Volumn 27, Issue 3, 2008, Pages 292-300

  Kinner, Stuart A ^a   Degenhardt, Louisa ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Dependence; Ecstasy; Epidemiology; Injecting drug use; Methamphetamine

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; CENTRAL STIMULANT AGENT; METHAMPHETAMINE; PSYCHEDELIC AGENT; STREET DRUG;

ADDICTION; ADULT; ARTICLE; AUSTRALIA; CRIME; CROSS-SECTIONAL STUDY; DRUG ABUSE; FEMALE; HARM REDUCTION; HEROIN DEPENDENCE; HIGH RISK BEHAVIOR; HOSPITALIZATION; HUMAN; MALE; PSYCHOLOGICAL RATING SCALE; QUESTIONNAIRE; SUBSTANCE ABUSE;

ADULT; AMPHETAMINE-RELATED DISORDERS; AUSTRALIA; CENTRAL NERVOUS SYSTEM STIMULANTS; CRIME; CROSS-SECTIONAL STUDIES; FEMALE; HALLUCINOGENS; HARM REDUCTION; HEROIN DEPENDENCE; HUMANS; MALE; METHAMPHETAMINE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; PSYCHIATRIC STATUS RATING SCALES; QUESTIONNAIRES; RISK-TAKING; SEVERITY OF ILLNESS INDEX; STREET DRUGS; SUBSTANCE ABUSE, INTRAVENOUS; SUBSTANCE-RELATED DISORDERS;

EID: 41549142256     PISSN: 09595236     EISSN: 14653362     Source Type: Journal    
DOI: 10.1080/09595230801919452     Document Type: Article

References (44)

1. Kaye S, McKetin R, Duflou J, Darke S. Methamphetamine and cardiovascular pathology: a review of the evidence. Addiction 2007;102:1204-11.
2. Hong R, Matsuyama E, Nur K. Cardiomyopathy associated with the smoking of crystal methamphetamine. JAMA 1991;265:1152-4.
3. Yu Q, Larson DF, Watson RR. Heart disease, methamphetamine and AIDS. Life Sci 2003;73:129-40.
4. Albertson E, Derlet RW, vanHoozen BE. Methamphetamine and the expanding complications of amphetamines. Western J Med 1999;170:214-23.
5. Degenhardt L, Topp L. 'Crystal meth' use among polydrug users in Sydney's dance party subculture: characteristics, use patterns and associated harms. Int J Drug Policy 2003;14:17-24.
6. Jernigan TL, Gamst AC, Archibald SL, et al. Effects of methamphetamine dependence and HIV infection on cerebral morphology. Am J Psychiatry 2005;162:1461-72.
7. Nordahl TE, Salo R, Leamon M. Neuropsychological effects of chronic methamphetamine use on neurotransmitters and cognition: a review. J Neuropsychiatry Clin Neurosci 2003;15:317-25.
8. Kalechstein AD, Newton TF, Green M. Methamphetamine dependence is associated with neurocognitive impairment in the initial phases of abstinence. J Neuropsychiatry Clin Neurosci 2003;15:215-20.
9. Derlet RW, Heischober B. Methamphetamine: stimulant of the 1990s? Western J Med 1990;153:625-9.
10. Heischober B, Miller MA. Methamphetamine abuse in California. In: Kozel MAMNJ, ed. Methamphetamine abuse: epidemiologic issues and implications. NIDA Research Monograph no. 115. Rockville, MD: National Institute on Drug Abuse, 1991:60-71.
11. Jackson JG. Hazards of smokable methamphetamine. N Engl J Med 1989,321:907.
12. Miller MA. Trends and patterns of methamphetamine smoking in Hawaii. In: Miller MA, Kozel NJ, eds. Methamphetamine abuse: epidemiologic issues and implications. NIDA Research Monograph no. 115. Rockville, MD: National Institute on Drug Abuse, 1991:72-83.
13. McKetin R, McLaren J, Lubman DI, Hides L. The prevalence of psychotic symptoms among methamphetamine users. Addiction 2006;101:1473-8.
14. Australian Institute of Health and Welfare (AIHW). 2004 National drug strategy household survey: detailed findings. Drug Statistics Series no. 16, AIHW Cat. Canberra: AIHW, 2005.
15. Farrell M, Marsden J, Ali R, Ling W. Methamphetamine: drug use and psychoses becomes a major public health issue in the Asia Pacific region. Addiction 2002;97:771-2.
16. Nappo SA, Noto AR, Galduroz JCF, Luiz E, Carlini A. 'Ice': an old drug returns in its most powerful route. J Brasil Psiquiatr 2001;50:57-62.
17. National Drug Intelligence Centre (NDIC). National drug threat assessment 2003. NDIC Report no. 2003-Q0317-001. Johnstown, PA: US Department of Justice, NDIC, 2003.
18. Sattah MV, Supawitkul S, Dondero TJ, et al. Prevalence of and risk factors for methamphetamine use in northern Thai youth: results of an audio-computer-assisted self-interviewing survey with urine testing. Addiction 2002;97:801 - 8.
19. Shaw K-P. Human methamphetamine-related fatalities in Taiwan during 1991-1996. J Forensic Sci 1999;44:27-31.
20. Topp L, Degenhardt L, Kaye S, Darke S. The emergence of potent forms of methamphetamine in Sydney, Australia: a case study of the IDRS as a strategic early warning system. Drug Alcohol Rev 2002;21:341-8.
21. Wilkins C, Rose E, Trappitt D, Sellman D, Adamson S, DeZwart K. Recent changes in the methamphetamine scene in New Zealand: preliminary findings from key informant surveys of drug enforcement officers and drug treatment workers. 2004. Available at: http://www.police.govt.nz/resources/2004/meth-scene/ (accessed 14 September 2005).
22. United Nations Office on Drugs and Crime (UNODC). 2005 World Drug Report, vol. 1. Analysis. Vienna: UNODC, 2005.
23. McKetin R, McLaren J, Kelly E. The Sydney methamphetamine market: patterns of supply, use, personal harms and social consequences. NDLERF Monograph no. 13. Sydney: National Drug and Alcohol Research Centre, University of NSW, 2005.
24. Australian Crime Commission (ACC). Illicit drug data report 2005-06. Canberra: ACC, 2007.
25. Laidler KAJ, Morgan P. Kinship and community: the 'ice' crisis in Hawaii. In: Klee H, ed. Amphetamine misuse: international perspectives on current trends. Amsterdam: Harwood Academic Publishers, 1997:163-79.
26. Matsumoto T, Kamijo A, Miyakawa T, et al. Methamphetamine in Japan: the consequences of methamphetamine abuse as a function of route of administration. Addiction 2002;97:809-17.
27. McKetin R, Kelly E, McLaren J. The relationship between crystalline methamphetamine use and methamphetamine dependence. Drug Alcohol Depend 2006;85:198-204.
28. Shaner JW, Kimmes N, Saini T, Edwards P. 'Meth mouth' Australian Crime Commission: rampant caries in methamphetamine abusers. AIDS Patient Care STDS 2006;20:146-50.
29. Klasser GD, Epstein J. Methamphetamine and its impact on dental care. J Can Dent Assoc 2005;71:759-62.
30. Harris DS, Boxenbaum H, Everhart ET, Sequeira G, Mendelson JE, Jones RT. The bioavailability of intranasal and smoked methamphetamine. Clin Pharmacol Ther 2003;74:475-86.
31. Cook CE. Pyrolytic characteristics, pharmacokinetics, and bioavailability of smoked heroin, cocaine, phencyclidine, and methamphetamine. In: Miller MA, Kozel NJ, eds. Methamphetamine abuse: epidemiologic issues and implications. NIDA Research Monograph no. 115. Rockville, MD: National Institute on Drug Abuse, 1991:6-23.
32. Cook CE, Jeffcoat AR, Hill JM, et al. Pharmacokinetics of methamphetamine self-administered to human subjects by smoking S-(+)-methamphetamine hydrochloride. Drug Metab Dispos 1993;21:717-23.
33. Newman JL, Carroll ME. Reinforcing effects of smoked methamphetamine in rhesus monkeys. Psychopharmacology 2006;188:193-200.
34. Stafford C, Degenhardt L, Agaliotis M, et al. Australian trends in ecstasy and related drug markets 2004: findings from the Party Drugs Initiative (PDI). NDARC Monograph, Report no. 57. Sydney: National Drug and Alcohol Research Centre, University of New South Wales, 2005.
35. Kinner SA, Degenhardt L. Reflections on the development and implementation of an early warning system for ecstasy and related drug markets in Australia. Drug Alcohol Rev 2006;25:445-9.
36. Topp L, Barker B, Degenhardt L. The external validity of results derived from ecstasy users recruited using purposive sampling strategies. Drug Alcohol Depend 2004;73:33-40.
37. Stafford J, Degenhard L, Dunn M, et al. Australian trends in ecstasy and related drug markets 2005: findings from the Party Drugs Initiative (PDI). NDARC Monograph, Report no. 58. Sydney: University of New South Wales, 2006.
38. Shand F, Topp L, Darke S, Makkai T, Griffiths P. The monitoring of drug trends in Australia. Drug Alcohol Rev 2003;22:61-72.
39. Darke S, Ward J, Hall W, Heather N, Wodak A. The Opiate Treatment Index (OTI) Manual. NDARC Technical Report no. 11. Sydney: National Drug and Alcohol Research Centre, University of New South Wales, 1991.
40. Gossop M, Darke S, Griffiths P, et al. The Severity of Dependence Scale (SDS): psychometric properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users. Addiction 1995;90:607-14.
41. Dawe S, Loxton NJ, Hides L, Kavanagh DJ, Mattick RP. Review of diagnostic screening instruments for alcohol and other drug use and other psychiatric disorders, 2nd edn. Canberra: Commonwealth Department of Health and Ageing, 2002.
42. Topp L, Mattick RP. Choosing a cut-off on the Severity of Dependence Scale (SDS) for amphetamine users. Addiction 1997;92:839-45.
43. Leonard L, DeRubeis E, Pelude L, Medd E, Birkett N, Seto J. 'I inject less as I have easier access to pipes': injecting, and sharing of crack-smoking materials, decline as safer crack-smoking resources are distributed. Int J Drug Policy 2007; doi:10.1016/j.drugpo.2007.02.008
44. Kinner SA, Degenhardt L. Reflections on the development and implementation of an early warning system for ecstasy and related drug markets in Australia. Drug Alcohol Rev 2006;25:445-9.